By the time AbbVie brought its first drug for hepatitis C to market, in December 2014, it was already too late.
Twelve months earlier, Gilead Sciences had secured U.S. approval for Sovaldi (sofosbuvir), offering hepatitis C patients a once-daily treatment regimen capable of clearing the virus in as little as three months.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,